Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 60, Issue 3, 2005, Pages 330-337

  Chapman, Kenneth R ^a,i   Patel, P ^b   D'Urzo, A D ^c   Alexander, M ^d   Mehra, S ^e,f   Oedekoven, C ^g   Engelstatter R ^g   Boulet, L P ^h  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b Allied Research International   (Canada)

^c Primary Care Lung Clinic   (Canada)

^d Allied Health Centre   (Canada)

^e Oshawa Clinic   (Canada)

^f PFIZER INC   (United States)

^g ALTANA PHARMA AG   (Germany)

^h LAVAL UNIVERSITY   (Canada)

ⁱ ECW   (Canada)

Author keywords

Asthma; Ciclesonide; Cortisol; Inhaled corticosteroids; Safety

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE; HYDROCORTISONE; PLACEBO; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; DYSPNEA; EVALUATION; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; LARYNX DISORDER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCORING SYSTEM; SORE THROAT; SPIROMETRY; SYMPTOM; THRUSH; UPPER RESPIRATORY TRACT INFECTION; WHEEZING; XEROSTOMIA;

ADMINISTRATION, INHALATION; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; PREGNENEDIONES; SALVAGE THERAPY; SPIROMETRY; TREATMENT OUTCOME;

EID: 14344250921     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2004.00750.x     Document Type: Article

References (25)

1. Boulet LP, Becker A, Beruhe D, Beveridge R, Ernst P. Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group. CMAJ 1999;161:S1-61.
2. National Institutes of Health: National Heart, Lung and Blood Institute. Asthma management and prevention. A practical guide for public health officials and health care professionals, Publication 96-3659A. Bethesda, MD: National Institutes of Health, 1995.
3. National Institutes of Health: National Heart, Lung and Blood Institute. National Asthma Education and Prevention Program. Expert Panel Report 2. Guidelines for the diagnosis and management of asthma, Publication 97-4051. Bethesda, MD: National Institutes of Health, 1997.
4. National Institutes of Health. Global initiative for asthma: Global strategy for asthma management and prevention. 2003. http://www.ginasthma.com. Accessed on June 16, 2004.
5. Halterman JS, Aligne CA, Auinger P, McBride JT, Szilagyi PG. Inadequate therapy for asthma among children in the United States. Pediatrics 2000;105:272-276.
6. Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 1998;113:587-592.
7. Wilson AM, Clark DJ, McFarlane L, Lipworth BJ. Adrenal suppression with high doses of inhaled fluticasone propionate and triamcinolone acetonide in healthy volunteers. Eur J Clin Pharmacol 1997;53:33-37.
8. Clark DJ, Grove A, Cargill RI, Lipworth BJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996;51:262-266.
9. Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol 1995;96:571-579.
10. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001;345:941-947.
11. Hubbard RB, Smith CJ, Smeeth L, Harrison TW, Tattersfield AE. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 2002;166:1563-1566.
12. Dietzel K, Engelstätter R, Keller A. Ciclesonide: an on-site-activated steroid. In: Hansel TT, Barnes PJ, editors. New drugs for asthma, allergy and COPD. Basel, Switzerland: Karger, 2001:91-93.
13. Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003;112(suppl.):S1-S40.
14. Postma DS, Sevette C, Martinat Y, Schlösser N, Aumann J, Kafé H. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 2001;17:1083-1088.
15. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-244.
16. American Thoracic Society. Standardization of spirometry, 1994 Update. Am J Respir Crit Care Med 1995;152:1107-1136.
17. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991;144:1202-1218.
18. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981;123:659-664.
19. Karch FE, Lasagna L. Adverse drug reactions: a critical review. JAMA 1975;234:1236-1241.
20. Gibson PG, Wong BJ, Hepperle MJ, Kline PA, Girgis-Gabardo A, Guyatt G et al. A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid. Clin Exp Allergy 1992;22: 525-532.
21. Löfdahl CG, Reiss TF, Leff JA, Israel E, Noonan MJ, Finn AF et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999;319:87-90.
22. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392-1397.
23. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-1411.
24. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998;157:S1-S53.
25. Taylor DA, Jensen MW, Kanabar V, Engelstätter R, Steinijans VW, Barnes PJ et al. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am J Respir Crit Care Med 1999;160:237-243.